RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
JOURNAL OF CLINICAL ONCOLOGY
Collezione ASL Città di Torino

Items : 15

Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial in Journal of Clinical Oncology

2023
AOU Città della Salute di Torino
ASL Città di Torino

Conte PF; Bisagni G; Piacentini F; Sarti S; Minichillo S; Anselmi E; Aieta M; Gebbia V; Schirone A; Musolino A; Garrone O; Beano A; Rimanti A; Giotta F; Turletti A; Dieci MV; Vicini R; Balduzzi S; D'Amico R; Guarneri V;

A rare case of metastatic testicular adult granulosa cell tumor in Journal of Clinical Oncology

2020
ASL Città di Torino

Delsedime L; Misischi F; Miraglia S; Taraglio S; Metovic J; Natoli G;

Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study in Journal of Clinical Oncology

2019
AOU Città della Salute di Torino
ASL Città di Torino

Cazzaniga ME; Pronzato P; Schettini F; Del Mastro L; Riemma M; Alu M; Turletti A; Giordano M; Pugliese P; De Angelis C; Garrone O; Marchetti P; Riccardi F; Bernardo A; Livi L; Fabi A; Taverniti C; De Placido S; Mustacchi G;

First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study in Journal of Clinical Oncology

2018
AOU Città della Salute di Torino
ASL Città di Torino

Pronzato P; Mustacchi G; Giordano M; Garrone O; Del Mastro L; Natoli C; Turletti A; Romagnoli E; Bologna A; Mocerino C; Alù M; De Angelis C; Aversa C; Arpino G; Taverniti C; Biganzoli L; Meattini I; Piezzo M; Cazzaniga ME;

Metronomic chemotherapy (mCHT) in HER2- ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study in Journal of Clinical Oncology

2018
AOU Città della Salute di Torino
ASL Città di Torino

Cazzaniga ME; Scognamiglio G; Generali DG; Ferzi A; Vandone AM; Spadaro P; Mocerino C; Montagna E; Cretella E; Gambaro A; Taverniti C; Turletti A; Sarobba G; Iezzi L; Roberto M; Ciccarese M; Tralongo P; Clivio L; Pedroli S; Torri V;

Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly- Preliminary results of the GIM-13 AMBRA study in Journal of Clinical Oncology

2018
AOU Città della Salute di Torino
ASL Città di Torino

Mustacchi G; Pronzato P; D'Alonzo A; Mocerino C; Romagnoli E; Garrone O; Blasi L; De Laurentiis M; Michelotti A; Bologna A; Giordano M; Turletti A; Montemurro F; De Placido S; Natoli C; Taverniti C; Biganzoli L; Meattini I; Marchetti P; Cazzaniga ME;

Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study in Journal of Clinical Oncology

2018
ASL Città di Torino

Mustacchi G; Piezzo M; D'Alonzo A; Mocerino C; Romagnoli E; Garrone O; Blasi L; Diodati L; Bologna A; Giordano M; Bordin E; Aversa C; De Placido S; Natoli C; Taverniti C; Biganzoli L; Meattini I; Pronzato P; Cazzaniga ME;

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER in Journal of Clinical Oncology

2017
ASL Città di Torino

Conte PF; Bisagni G; Frassoldati A; Brandes AA; Anselmi E; Giotta F; Aieta M; Gebbia V; Musolino A; Garrone O; Taverniti C; Cavazzini G; Turletti A; Rubino D; Picardo E; Ferro A; Piacentini F; Balduzzi S; D'Amico R; Guarneri V;

The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study in Journal of Clinical Oncology

2017
ASL Città di Torino

Mustacchi G; Cazzaniga ME; Romagnoli E; Montemurro F; De Laurentiis M; Riccardi F; Turletti A; Beano A; De Angelis C; Graziano V; Livi L; Del Mastro L; Biganzoli L; Garrone O; De Placido S; Marchetti P; Pronzato P;

Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts) in Journal of Clinical Oncology

2017
ASL Città di Torino

Cazzaniga ME; Mustacchi G; Romagnoli E; Montemurro F; Caporello P; De Laurentiis M; Riccardi F; Turletti A; De Angelis C; Graziano V; Livi L; Del Mastro L; Beano A; Garrone O; Biganzoli L; Pronzato P; De Placido S;

Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study in Journal of Clinical Oncology

2017
ASL Città di Torino

Mustacchi G; Cazzaniga ME; Giordano M; Garrone O; Beano A; Del Mastro L; Livi L; Iezzi L; Michelotti A; Turletti A; Riccardi F; De Laurentiis M; Marchetti P; Biganzoli L; Montemurro F; Romagnoli E; De Placido S; Pronzato P;

Establishment of patient-derived renal cell carcinoma (RCC) models based on orthotopic xenografts (PDX) and cancer stem cell (CSC) isolation to provide prognostic and predictive information in Journal of Clinical Oncology

2017
ASL Città di Torino

Di Martino S; De Luca G; Grassi L; Federici G; De Salvo L; Di Pace AL; Addario A; Muto G; Costantini M; Biffioni M; Signore M; Sperduti I; Sentinelli S; Milella M; Cognetti F; Gallucci M; De Maria R; Bonci D;

Low doses of ketoconazole and prednisone in patients with castration resistant prostate cancer (CRPC): A retrospective study on 73 patients in Journal of Clinical Oncology

2013
ASL Città di Torino

Amaniera G; Ballatore V; Ruatta F; Prati V; D'Urso L; Muto G; Aglietta M; Ortega C;

Intra-arterial infusion of irinotecan loaded microparticles (IAIRIM) for symptomatic and unresectable colorectal cancer (UCRC): Preliminary report in Journal of Clinical Oncology

2013
ASL Città di Torino

Comelli S; Bini R; Gallo G; Savio D; Viora T; Vaudano GP; Leli R;

Efficacy of low-dose ketoconazole in the treatment of castration-resistant prostate cancer (CRPC): A single-institution experience in Journal of Clinical Oncology

2012
ASL Città di Torino

Ortega C; Ruatta F; Prati V; Ballatore V; Capaldi A; Garibaldi E; Gabriele P; Muto G; Aglietta M;